Actas urologicas espanolas最新文献

{"title":"Comment on \"Profile of patients with clean intermittent catheterization and associated resource consumption. Multicenter study in Spain\".","authors":"R Mehta, R Sah","doi":"10.1016/j.acuroe.2025.501795","DOIUrl":"10.1016/j.acuroe.2025.501795","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501795"},"PeriodicalIF":0.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is retroperitoneal access feasible using the single-port robotic platform for native nephrectomy after kidney transplantation?","authors":"H B Haberal, F M Valenzi, V Santarelli, S Crivellaro","doi":"10.1016/j.acuroe.2025.501797","DOIUrl":"10.1016/j.acuroe.2025.501797","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501797"},"PeriodicalIF":0.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pure embryonal carcinoma of the testis: A new case report and review of the literature","authors":"C. Ramírez Sevilla , M. Puyol Pallàs , D.H. Llanos Manzano , Y. Zboromirskyy Pronuk","doi":"10.1016/j.acuroe.2025.501693","DOIUrl":"10.1016/j.acuroe.2025.501693","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501693"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease","authors":"R. Pichler ,&nbsp;N.C.H. van Creij ,&nbsp;J.D. Subiela ,&nbsp;A. Cimadamore ,&nbsp;J. Caño-Velasco ,&nbsp;K.H. Tully ,&nbsp;K. Mori ,&nbsp;R. Contieri ,&nbsp;L. Afferi ,&nbsp;A. Mari ,&nbsp;F. Soria ,&nbsp;F. Del Giudice ,&nbsp;C. D’Elia ,&nbsp;R. Mayr ,&nbsp;L.S. Mertens ,&nbsp;N. Pyrgidis ,&nbsp;M. Moschini ,&nbsp;A. Gallioli ,&nbsp;Asociación Europea de Urología-Jóvenes Urólogos Académicos (EAU-YAU): Grupo de Trabajo de Carcinoma Urotelial","doi":"10.1016/j.acuroe.2025.501719","DOIUrl":"10.1016/j.acuroe.2025.501719","url":null,"abstract":"<div><div>FGFR3 mutations are among the most frequent genomic alterations in urothelial cancer (UC) being mainly associated with the luminal papillary (LumP) subtype. With the establishment of fibroblast growth factor receptor (FGFR) inhibitors, the treatment of UC is now shifting more and more towards personalized medicine. A systematic review using Medline and scientific meeting records was carried out according to the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines to assess the potential role of FGFR inhibitors in combination with additional therapies for the management of UC. Ongoing trials were identified via a systematic search on ClinicalTrials.gov. A total of eleven full-text papers, ten congress abstracts, and 5 trials on ClinicalTrials.gov were identified. Following the BLC2001 and THOR study, erdafitinib is the only approved FGFR1-4 inhibitor for metastatic UC with susceptible FGFR2/3 alterations following platinum-based chemotherapy. According to the THOR data of cohort 2, erdafitinib should not be recommended in patients who are eligible for and have not received prior immune checkpoint inhibitors (ICIs). One phase 3 trial is currently evaluating the intravesical device system (TAR210) in FGFR-altered intermediate non-muscle invasive bladder cancer (MoonRISe-1). Preclinical evidence suggests that combination-based approaches could be considered to improve the efficacy of FGFR inhibitors in patients with UC. Nine phase 1b/2 trials are focusing on the combination of FGFR inhibitors with ICIs, chemotherapy, or enfortumab vedotin. In metastatic disease, some preliminary analyses have reported promising results from these combinations (e.g. NORSE and FORT-2 trial). However, no phase 3 trial is terminated, so there is currently no level 1 evidence with long-term outcomes to support the combination of FGFR inhibitors with ICIs, chemotherapy, or targeted therapies. A better understanding of the different mechanisms of action to inhibit FGFR signaling pathways, optimal patient selection and treatment approaches is still needed.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501719"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on «The use of robotic surgery for the management of urethral strictures and bladder neck contractures: A systematic review»","authors":"R. Mehta ,&nbsp;S. Kumar","doi":"10.1016/j.acuroe.2025.501739","DOIUrl":"10.1016/j.acuroe.2025.501739","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501739"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the type of anaesthesia influence the outcome of percutaneous nephrolithotomy? Outcomes from a meta- analysis of randomized controlled trials","authors":"C. Giulioni ,&nbsp;A. Singh ,&nbsp;S.K. Yuen ,&nbsp;C. Nedbal ,&nbsp;V. De Stefano ,&nbsp;E.J. Lim ,&nbsp;M. Langer Wroclawski ,&nbsp;C.A. Chai ,&nbsp;M. Maggi ,&nbsp;A. Cafarelli ,&nbsp;D. Castellani ,&nbsp;R. Tp ,&nbsp;A. Satapathy ,&nbsp;V. Gauhar","doi":"10.1016/j.acuroe.2025.501755","DOIUrl":"10.1016/j.acuroe.2025.501755","url":null,"abstract":"<div><h3>Objective</h3><div>To systematically review the outcomes of percutaneous nephrolithotomy (PCNL) performed in local (LA) or regional anesthesia (RA) as compared to general anesthesia (GA).</div></div><div><h3>Methods</h3><div>Literature search was conducted on 12th April 2024 including PubMed, Medline, Embase, and Scopus database. Complications were assessed using the Cochran-Mantel-Haenszel Method with the random effect model and reported as odds ratio (OR), 95% confidence interval (CI), and p-values. Analyses were two-tailed and the significance was set at p &lt; 0.05 and a 95% CI. Continuous variables were pooled using the inverse variance of the mean difference with a random effect, 95% CI, and p-values.</div></div><div><h3>Results</h3><div>Fourteen studies were included. Overall, there were 1413 patients, with 703 patients in the LA/RA group and 710 in the GA group. There was no difference in Clavien grade I<img>II and ≥III complications, postoperative pain, postoperative headache, operative time, postoperative stay, stone-free rate, and intraoperative mean heart rate between LA/RA and GA. Meta-analysis shows that the nausea and vomiting rate favors the LA/RA group (OR 0.10), blood transfusion rate is lower in LA/RA group (OR 0.40), intraoperative blood loss is lower in LA/RA group (MD −59.63 ml) and intraoperative mean arterial pressure is lower in LA/RA group (MD −10.80 mmHg).</div></div><div><h3>Conclusions</h3><div>This meta-analysis shows no difference in stone-free and complication rates or hospital stay if PCNL is done under GA or LA/RA. LA/RA offers advantages for better intraoperative hemodynamic stability with lesser post-operative nausea and vomiting. PCNL under RA adoption in clinical practice is perhaps limited to centers where specialist anesthetist services can support this procedure.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501755"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Same-sitting bilateral Retrograde IntraRenal Surgery for renal stone in patients aged 70 years and above","authors":"C. Giulioni ,&nbsp;V. De Stefano ,&nbsp;O. Traxer ,&nbsp;D. Ragoori ,&nbsp;N. Gadzhiev ,&nbsp;Y. Tanidir ,&nbsp;T. Inoue ,&nbsp;E. Emiliani ,&nbsp;S. Bin Hamri ,&nbsp;M. Amine Lakmichi ,&nbsp;C. Mohan Vaddi ,&nbsp;C. Tiong Heng ,&nbsp;B. Soebhali ,&nbsp;S. More ,&nbsp;V. Sridharan ,&nbsp;M. Ilker Gökce ,&nbsp;A.N. Tursunkulov ,&nbsp;A. Ganpule ,&nbsp;G.M. Pirola ,&nbsp;A. Naselli ,&nbsp;D. Castellani","doi":"10.1016/j.acuroe.2025.501716","DOIUrl":"10.1016/j.acuroe.2025.501716","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate outcomes of same sitting Bilateral Retrograde IntraRenal Surgery (SSB-RISRS) for kidney stone in patients aged ≥70 years.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed patients with bilateral kidney stones who underwent SSB-RISRS in 21 centers (January 2015-June 2022). Inclusion criteria: patients aged ≥70 years, bilateral kidney stones diagnosed due to either unilateral or bilateral symptomatic presentation. Patients were divided into 2 groups. Group 1: patients aged 70–74 years, Group 2: patients aged ≥75 years.</div></div><div><h3>Results</h3><div>There were 86 patients in Group 1 and 60 patients in Group 2. There was no difference between the groups for gender, ASA score, BMI, comorbidities, presenting symptoms, and positive preoperative urine culture. Group 2 had a significantly higher proportion of recurrent stone formers (54.7% vs 35.0%, p<!--> <!-->=<!--> <!-->0.03). A higher proportion of bilaterally pre-stented patients were present in group 2 (37.9% vs 18.6%). There was no difference in total operation time and rate of post-operative uni- and bilateral stent positioning. Surgery was discontinued in 15.1% and 18.3% of cases in groups 1 and 2, respectively (p<!--> <!-->=<!--> <!-->0.773). Median length of postoperative stay was 2 days in both groups. The most frequent complication was fever requiring antibiotics and prolonged admission (10.5% in group 1 and 11.7% in group 2, p<!--> <!-->&gt;<!--> <!-->0.99). Sepsis rate was 2.3% patients in group 1 and none in group 2. 1.2% in group 1 required a blood transfusion due to hematuria. Bilateral SFR was similar (60.0% vs 47.7%, p<!--> <!-->=<!--> <!-->0.194).</div></div><div><h3>Conclusions</h3><div>SSB-RISRS in elderly patients demonstrated an acceptable safety profile with good bilateral SFR.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501716"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients","authors":"M. Hassi Roman ,&nbsp;K. Mate ,&nbsp;P. de Pablos-RodrIguez ,&nbsp;Á. Zamora Horcajada ,&nbsp;A. Guijarro Cascales ,&nbsp;Á. Sanchís Bonet ,&nbsp;A. Vilaseca ,&nbsp;D. Vázquez-Martul Pazos ,&nbsp;E. Linares Espinós ,&nbsp;J. Muñoz Rodríguez ,&nbsp;J.M. de la Morena Gallego ,&nbsp;J.R. Alemán ,&nbsp;J. Gómez Rivas ,&nbsp;L. Formisano ,&nbsp;M.J. Juan Fita ,&nbsp;M. Costa Planells ,&nbsp;M. Domínguez Esteban ,&nbsp;M. Pérez Márquez ,&nbsp;M. García Sanz ,&nbsp;N. García Expósito ,&nbsp;M. Ramírez Backhaus","doi":"10.1016/j.acuroe.2025.501742","DOIUrl":"10.1016/j.acuroe.2025.501742","url":null,"abstract":"<div><h3>Introduction</h3><div>Apalutamide has shown significantly increases in radiographic progression-free survival (rPFS) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients diagnosed by conventional imaging (CI). However, there is scarce knowledge on the use of apalutamide in mHSPC population diagnosed by NGI.</div></div><div><h3>Methods</h3><div>Retrospective multicenter study of mHSPC patients treated with apalutamide from May 2018 to September 2023 registered in the Real-World Evidence APA (RWE-APA). CI and NGI group were defined, according to the diagnostic tool of metastatic disease. Primary objective was rPFS at 24 mo in CI vs NGI group. Secondary objectives were OS in CI vs NGI group and rPFS in synchronic/metachronic, low volume (LV)/high volume (HV) in CI and NGI groups and risk of developing new metastasis according to the imaging technique, metastasis volume and location of the metastasis.</div></div><div><h3>Results</h3><div>772 mHSPC patients were included. 47% (359) of patients were diagnosed with CI and 53% (413) of patients with NGI. rPFS at 24 mo was 80% in the CI group vs 84% in the NGI group (Hazard ratio (HR): 0.57 (0.35–0.92) 95% Confidence Interval [CI], p = 0.023). OS at 24 mo was 89.5% in the CI group and 95.8% in the NGI group (HR 0.35; 95% CI, 0.16–0.75, p = 0.007). In the multivariable analysis, only HV was significantly associated with metastatic progression (HR 0.33 (0.18–0.59) 95% CI; p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>mHSPC patients treated with apalutamide and NGI-diagnosed exhibited superior rPFS and OS in comparison with CI-diagnosed patients.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501742"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of postvoid residual urine volumes among lower urinary tract parameters in pediatric and adolescent age groups: A cohort study at a tertiary referral center","authors":"Y. Emre Genc ,&nbsp;C. Akin Sekerci ,&nbsp;O. Can Ozkan ,&nbsp;D. Dorucu ,&nbsp;F. Arslan ,&nbsp;R. Ergun ,&nbsp;S. Yucel ,&nbsp;T. Tarcan","doi":"10.1016/j.acuroe.2025.501752","DOIUrl":"10.1016/j.acuroe.2025.501752","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Uroflowmetry and postvoid residual urine volume measurement remain essential in evaluating patients with lower urinary tract dysfunction. The objective was to identify patients with a high risk of infection or renal damage based on the lower urinary tract parameters.</div></div><div><h3>Materials and methods</h3><div>Over a one-year period we investigated patients who had an indication for uroflowmetry and postvoid residual urine volume measurement between 5–18 years of age. All parameters were prospectively recorded. After the initial evaluation, patients were divided into increased/normal postvoid residual urine volume groups. Lower urinary tract parameters, urinary tract infection and hydronephrosis status were analyzed.</div></div><div><h3>Results</h3><div>A total of 176 girls and 140 boys with an age of 9 (5–16) were assessed. When increased (<em>n</em> = 135)/normal postvoid residual urine volume (<em>n</em> = 181) groups of patients were analyzed, patients with a diagnosis of dysfunctional voiding, staccato and interrupted-shaped flow pattern, decreased Qavg, increased micrution duration, decreased daytime voiding frequency, and constipation were found to be prone to increased postvoid residual urine volume. A diagnosis of overactive bladder or dysfunctional voiding and high postvoid residual urine volume were both found to be related to infections.</div></div><div><h3>Conclusions</h3><div>We contributed to the literature by evaluating different types of lower urinary tract conditions and their clinical parameters to better understand the predisposing factors to detect patients at risk of infections or renal damage such as dysfunctional voiding, staccato and interrupted-shaped flow pattern, constipation, decreased Qavg, prolonged duration of micturition and decreased daytime voiding frequency regardless of age and gender status.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501752"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of opium on bladder cancer incidence: A systematic review and meta-analysis","authors":"S. Mancon ,&nbsp;A. Matsukawa ,&nbsp;A. Cadenar ,&nbsp;I. Tsuboi ,&nbsp;M. Miszczyk ,&nbsp;M.K. Parizi ,&nbsp;T. Fazekas ,&nbsp;R.J. Schulz ,&nbsp;A. Cormio ,&nbsp;E. Laukhtina ,&nbsp;A. Gallioli ,&nbsp;P. Diana ,&nbsp;R. Contieri ,&nbsp;F. Soria ,&nbsp;B. Pradere ,&nbsp;G. Lughezzani ,&nbsp;T. Kimura ,&nbsp;A. Territo ,&nbsp;A. Breda ,&nbsp;N.M. Buffi ,&nbsp;D. D’Andrea","doi":"10.1016/j.acuroe.2025.501749","DOIUrl":"10.1016/j.acuroe.2025.501749","url":null,"abstract":"<div><h3>Introduction</h3><div>Opium is used recreationally and for pain relief in certain regions and has been classified as a human carcinogen by the IARC. While its use is rare in Europe and Oceania, it remains a major public health issue in other parts of the world. This study evaluates the risk of bladder cancer (BCa) among opium users compared to non-users.</div></div><div><h3>Methods</h3><div>A comprehensive search of MEDLINE, Scopus, and Web of Science was conducted up to July 2024 to identify studies examining the link between opium use and BCa. A meta-analysis was performed to calculate the pooled risk ratio (RR) with 95% confidence intervals (CIs) (PROSPERO: CRD42024562623).</div></div><div><h3>Results</h3><div>A total of 15 studies (n<!--> <!-->=<!--> <!-->60,149) were included. The analysis showed that opium users had a significantly higher risk of developing BCa than non-users (RR: 2.36; 95% CI: 1.92–2.90; <em>P</em> <!-->&lt;<!--> <!-->.001). The risk increased with the amount of opium consumed, regardless of type or method of use.</div></div><div><h3>Conclusions</h3><div>Opium consumption increase the risk of developing BCa by more than twofold among users. Awareness of its carcinogenic potential and public health implications is crucial. Our findings underscore the need for global prevention strategies and further research into opium-related BCa risks.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501749"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}